First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma : CheckMate 649 Chinese subgroup analysis
© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC..
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:152 |
|---|---|
| Enthalten in: |
International journal of cancer - 152(2023), 4 vom: 15. Feb., Seite 749-760 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Tianshu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.12.2022 Date Revised 15.04.2023 published: Print-Electronic ClinicalTrials.gov: NCT02872116 Citation Status MEDLINE |
|---|
| doi: |
10.1002/ijc.34296 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346383528 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346383528 | ||
| 003 | DE-627 | ||
| 005 | 20231226031318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ijc.34296 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346383528 | ||
| 035 | |a (NLM)36121651 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Tianshu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma |b CheckMate 649 Chinese subgroup analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.12.2022 | ||
| 500 | |a Date Revised 15.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02872116 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. | ||
| 520 | |a First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Asian Continental Ancestry Group | |
| 650 | 4 | |a gastrointestinal neoplasms | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a nivolumab | |
| 650 | 4 | |a stomach neoplasms | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 650 | 7 | |a Oxaliplatin |2 NLM | |
| 650 | 7 | |a 04ZR38536J |2 NLM | |
| 650 | 7 | |a Ipilimumab |2 NLM | |
| 700 | 1 | |a Bai, Yuxian |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Xiaoyan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jufeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiaochun |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Hongming |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Chunmei |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jingdong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Haijun |e verfasserin |4 aut | |
| 700 | 1 | |a Ba, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Wenwei |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Ruihua |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Weijian |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Shukui |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Nong |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Jianwei |e verfasserin |4 aut | |
| 700 | 1 | |a Shitara, Kohei |e verfasserin |4 aut | |
| 700 | 1 | |a Lei, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Mingshun |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Tian |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Lin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cancer |d 1966 |g 152(2023), 4 vom: 15. Feb., Seite 749-760 |w (DE-627)NLM000004383 |x 1097-0215 |7 nnns |
| 773 | 1 | 8 | |g volume:152 |g year:2023 |g number:4 |g day:15 |g month:02 |g pages:749-760 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ijc.34296 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 152 |j 2023 |e 4 |b 15 |c 02 |h 749-760 | ||